Galapagos Licenses Asthma and Allergy Targets, Provides Research to GSK | GenomeWeb

NEW YORK, Jan. 5 (GenomeWeb News) - Galapagos has licensed asthma and allergy drug targets to GlaxoSmithKline and will identify further targets for the drug maker, the Mechelen, Belgium-based company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.